top of page
The Professional Network for Healthcare Experts
argenx agrees to acquire Unnatural Products for up to $1.15 billion to expand peptide drug discovery
argenx has agreed to acquire macrocyclic peptide specialist Unnatural Products in a transaction worth up to $1.15 billion, combining a substantial upfront payment with development-dependent milestones to expand beyond antibody therapeutics.
nuaxia
23 hours ago2 min read
argenx agrees to acquire Forte Biosciences for approximately $2.2 billion
The acquisition gives argenx full ownership of FB102, expanding its immunology pipeline with a first-in-class anti-CD122 antibody that has shown early clinical proof of concept in autoimmune disease.
nuaxia
Jul 282 min read
bottom of page